3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
19
Recruiting
6
Terminated
4
Active not recruiting
3
Withdrawn
1
Unknown
1
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
36
Tumor-Agnostic
1
Thoracic
1
Endocrine
1
Conditions
Adenocarcinoma
1
Interventions
Standard of Care
4
Radiotherapy
4
Oxaliplatin
4
tislelizumab
3
trastuzumab deruxtecan
2
pembrolizumab
2
cemiplimab
2
anlotinib
2
Radiation
2
Paclitaxel
2
Capecitabine
2
130-nm albumin-bound paclitaxel
2
vedolizumab
1
trametinib
1
toripalimab
1
surufatinib
1
ivosidenib
1
disitamab vedotin
1
coenzyme Q10
1
blinatumomab
1
Whole Genome Sequencing
1
Ursodeoxycholic Acid
1
Ultrasonography
1
Tretinoin
1
Thymopentin
1
Surgical Procedures, Operative
1
Sequence Analysis, RNA
1
Respiratory Rate
1
Radiotherapy, Intensity-Modulated
1
Radiosurgery
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Not yet recruiting
×
Leucovorin
×
Tumor-Agnostic
×
Clear all
NCT07118800
2025-08-12
NACRE-2
UNICANCER
Phase 3
Not yet recruiting
160 enrolled